Clinical trial
Phase I Study of γδT Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies
NCT02656147 is registered in ClinicalTrials.gov with Beijing Doing Biomedical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Study of γδT Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies
- Lead sponsor
- Beijing Doing Biomedical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- October 31, 2017
- Completion date
- April 30, 2020
- Enrollment
- 48 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.